Search Results - Michael Keng

  • Showing 1 - 2 results of 2
Refine Results
  1. 1
    The oral CDK9 inhibitor voruciclib combined with venetoclax for patients with relapsed/refractory acute myeloid leukemia

    The oral CDK9 inhibitor voruciclib combined with venetoclax for patients with relapsed/refractory acute myeloid leukemia by Yesid Alvarado-Valero, Rachel J. Cook, Shira N. Dinner, Michael Keng, Kebede H. Begna, Nathalie Javidi-Sharifi, Sameem Abedin, Monzr M. Al Malki, Vijaya Raj Bhatt, Prabhu Rajagopalan, Min Tang, Sandra E. Wiley, Richard G. Ghalie, Matthew S. Davids

    Published 2025-08-01
    Get full text
    Article

    Save to List
    Saved in:
  2. 2
    Real-world analysis of strategies to prevent thrombosis and bleeding in adults with ALL treated with asparaginase

    Real-world analysis of strategies to prevent thrombosis and bleeding in adults with ALL treated with asparaginase by Joseph F. Mort, David Brighton, Benjamin Mautner, Eric Pierce, Farid Ghamsari, Cecily Allen, Darren D’Souza, Imari Patel, Justin Lawson, Clayton Jackson, Karin Abernathy, Bradley Yelvington, Ryan Miller, Bhagirathbhai Dholaria, Heather Wolfe, Jordan Infield, Susan C. Locke, Rory M. Shallis, Vu H. Duong, Daniel R. Reed, Katherine Walsh, Thomas W. LeBlanc, Michael Keng, Bethany Horton, Firas El Chaer

    Published 2025-08-01
    Get full text
    Article

    Save to List
    Saved in:

Search Tools: